This medicine is applied across domains where additional symptomatic support is needed in acute cardiac situations.

---

Supporting the Heart During Acute Failure Crises

This medicine is commonly used to help manage the severe and distressing symptoms related to systemic imbalance that accompany acutely decompensated severe chronic heart failure. It is typically applied in clinical settings that involve acute or unstable symptom patterns where conventional therapy is considered insufficient and supportive symptom management is appropriate. It is commonly used across conditions presenting with acute episodes characterized by symptomatic manifestations and where temporary assistance in symptom stabilization is needed.

“It may provide support that helps ease the overall symptom burden of conditions characterized by periods of heightened symptoms.”

It may be part of symptomatic management applied in settings marked by temporary physiological imbalance. It contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Profound Symptomatic Burden

The medication is relevant for easing symptoms that interfere with daily functioning, such as severe shortness of breath and fluid retention. It is applied in scenarios where additional management of discomfort is required to assist with managing heightened symptomatic manifestations, provides supportive relief when symptoms interfere with routine activities. This treatment is also considered relevant when supportive symptom management is appropriate for certain patients who need short-term scenarios where additional management of discomfort is required.

Eligibility Map: Who Can and Cannot Use Levosimendan — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

• Adults with acutely decompensated severe chronic heart failure requiring inotropic support when conventional therapy is not sufficient.

Populations for whom use is contraindicated:

Official regulatory documents classify the following conditions as contraindications, meaning the medicine must not be used:

• Severe Hypotension and Tachycardia: Severe low blood pressure or excessively fast heart rate.
• Organ Impairment: Severe hepatic impairment and severe renal impairment (creatinine clearance < 30 mL/min).
• Cardiovascular Obstructions: Significant mechanical obstructions that affect the heart's function, such as severe aortic stenosis.
• Arrhythmia History: A history of a life-threatening abnormal heart rhythm called Torsades de Pointes.

Age-related eligibility rules:

• Pediatric Use: Levosimendan is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.
• Older Adults: No specific dose adjustment is required for elderly patients.

Pregnancy and lactation eligibility status:

• Pregnancy: Use is generally restricted and considered only if the potential benefits for the mother outweigh the possible risks to the foetus.
• Lactation: Women receiving Levosimendan should not breastfeed, as its active metabolites are known to be excreted into human milk.

Eligibility-related restrictions:

• The drug must be used with caution in patients with mild to moderate renal or hepatic impairment, requiring an extended period of patient monitoring. Caution is also advised in patients with low baseline blood pressure or pre-existing ischaemic heart disease.

Interactions with Other Medicines and Products

The official regulatory profile for Levosimendan structures interaction information around documented pharmacodynamic potentiation risks and specific notes on altered metabolite exposure due to clearance issues.

Interaction Category	Documented Outcome/Restriction (Official Labeling)
Haemodynamic Potentiation	Increased risk of hypotension when co-administered with other intravenous vasoactive medicinal products. Concomitant use with isosorbide mononitrate significantly potentiates the orthostatic hypotensive response.
Cardiac Rhythm Monitoring	Close ECG monitoring is required with medicinal products that prolong the QTc interval.
Pharmacokinetic Non-Interaction	No clinically significant pharmacokinetic interactions have been demonstrated with Digoxin or Warfarin.
Excipient Note	The excipient, anhydrous ethanol (alcohol), present in the concentrate formulation, may alter the effects of co-administered medicines.

Population-Specific Exposure Notes

In patients with severe hepatic impairment or severe renal impairment (creatinine clearance <30 ml/min), reduced clearance results in increased concentrations and prolonged exposure to the active metabolites. This population-dependent alteration in systemic exposure can lead to a more pronounced and prolonged haemodynamic effect. The drug can be administered with beta-blocking agents without a loss of therapeutic efficacy.

How Левосимендан Works

Левосимендан is an agent with positive inotropic and vasodilating properties that acts via two primary pharmacodynamic mechanisms.

1. Calcium Sensitization: The drug selectively targets cardiac troponin C ( TnC). It modulates the binding kinetics of calcium ions to TnC, which increases the responsiveness of the contractile proteins. This action alters cardiac contractility without increasing myocardial oxygen demand or impairing myocardial relaxation.

2. K ATP Channel Opening: Левосимендан acts on ATP-sensitive potassium channels ( K ATP) found in vascular smooth muscle. Opening these channels leads to hyperpolarization and vascular smooth muscle relaxation (vasodilation), which consequentially reduces both preload and afterload on the system. Furthermore, K ATP channel activity in the cardiac myocardium is associated with modulation of cellular processes.

Instruction Map: How to use Левосимендан — Administration Guidelines

Feature	Guideline
Route of Administration	Intravenous (IV) infusion only, delivered via a peripheral or central line.
Dosing Schedule (Adult)	A continuous, weight-based infusion administered within the range of 0.05 to 0.2 mug/kg/min. A starting loading dose of 6 to 12 mug/kg infused over 10 minutes may precede the continuous infusion.
Preparation Requirements	Mandatory dilution of the 2.5 mg/mL concentrate is required before use, typically with 5% glucose or 0.9% sodium chloride. The final diluted concentration must not exceed 0.05 mg/mL.
Special Procedural Conditions	The administration must occur in a hospital setting with continuous haemodynamic monitoring. Delivery is managed using a controlled infusion pump.

---

Instruction Classifications (High-Level)

Classification	Parameter
Administration method type	Intravenous (IV) Infusion.
Frequency pattern	Continuous infusion for a fixed duration of 24 hours.
Basis of use	Standard clinical protocols for cardiac support.
Use-context constraints	Hospital setting required for administration and monitoring.

---

Procedural Structure and Protocol

Standardized, short-term protocols for Levosimendan delivery involve specific administration steps. The medicine is administered as a single, 24-hour continuous infusion after the concentrate has been meticulously diluted to the correct strength. Dose adjustments are made based on clinical response, maintaining the rate within the established range. For patients with mild to moderate renal or hepatic impairment, extended haemodynamic monitoring is necessary for up to 5 days following the infusion due to the drug's prolonged effects.

Research Evidence / Overview of Studies for Левосимендан

Evidence for Use in Acute Severe Heart Failure

The majority of evidence on Levosimendan was evaluated in Randomized Controlled Trials (RCTs) focusing on acute severe heart failure. These short-term studies, often compared with standard therapies or a placebo, research examined whether the drug was associated with changes in heart’s pumping function and studies explored outcomes related to physical discomfort, such as severe shortness of breath. The populations studied for this indication were typically adults experiencing a sudden, severe worsening of their chronic heart failure.

Findings indicate patterns related to heart function in the short-term, with many studies reporting a measurable change in certain hemodynamic parameters. When studies explored differences compared to a standard therapy, some research describes patterns related to survival, but when compared to a placebo, findings were mixed regarding patterns observed in long-term survival. Therefore, research provides insight into short-term changes measured during the immediate treatment period, but the certainty remains low for long-term clinical outcomes when assessed against placebo.

Studies for Cardiac Function Support After Heart Surgery

The evidence here was evaluated in both Randomized Controlled Trials and observational settings that focused on patient outcomes. Research examined the drug in patients who were at risk of, or who had developed, low cardiac output syndrome (LCOS) following major heart surgery. The primary outcomes monitoring physiological strain included the frequency of LCOS, the duration of mechanical ventilation, and the amount of time patients spent in the Intensive Care Unit (ICU).

Long-Term Follow-up and Advanced Heart Failure Strategies

While the medicine was studied for short-term, acute support, studies explored its evaluation in a chronic, advanced heart failure context through intermittent or repetitive infusions over longer periods. This research was studied for patients with severe functional limitations, often as a strategy when other treatments had reached their limit.

Evidence in Special and High-Risk Patient Populations

Research examined the use of Левосимендан in specific patient populations, including older adults and pediatric patients (infants and children). For pediatric patients, data are still emerging from small Randomized Controlled Trials. Overall, the certainty remains low for major clinical outcomes in children, and the data for certain groups remain insufficient.

Areas of Uncertainty and Research Gaps

Despite the research conducted, several areas of uncertainty remain. Inconsistent Mortality Findings and Limited Long-Term Data are key issues. The primary evidence was derived from short-term trials, meaning there is limited information for long-term outcomes or how studies observed responses over defined time intervals following the initial treatment. Comparative evidence is lacking in some of these specialized areas.

Common questions about Левосимендан (FAQ)

Q: Is Levosimendan the same as other heart medicines, and if not, how is it different?

Official documents classify Levosimendan as a calcium sensitizer and an inodilator. This means the drug is described as modulating heart muscle contraction by increasing its sensitivity to the calcium already present in the cells. This mechanism is different from some other heart-strengthening medicines because it is designed to act without a significant increase in the heart's own oxygen demand.

Q: How long does the effect of Levosimendan typically last after the infusion is finished?

The drug has an active metabolite called OR-1896, which stays in the body after the 24-hour infusion is complete. Because of this metabolite, the effects on heart function and circulation may be observed for up to seven to nine days after the infusion is stopped.

Q: Does Levosimendan interact with common blood thinners?

Official regulatory labeling focuses on specific drug interactions. It states that, based on pharmacokinetic studies, no clinically significant interactions have been demonstrated when Levosimendan is used with Warfarin, which is a common blood thinner.

Q: Are there age restrictions for who can receive Levosimendan?

Yes, official product information states that the drug is not recommended for use in children and adolescents under 18 years of age because its safety and efficacy have not been established in this age group. However, no specific dose adjustment is required for elderly adult patients.

Q: What does clinical research say about repeated use of Levosimendan?

While the primary indication is for a single short-term treatment, research has explored the use of intermittent or repetitive infusions for patients with advanced heart failure. These studies have reported observed patterns of benefits related to heart function, neurohormone levels, and patient symptoms.

Q: What conditions make a patient ineligible for Levosimendan?

Official documents classify several conditions as contraindications. This means the drug is generally excluded from use in patients with severe low blood pressure, severe impairment of the liver or kidneys, certain mechanical obstructions affecting heart function, and a history of a life-threatening abnormal heart rhythm called Torsades de Pointes.

Q: Is Levosimendan associated with any changes to heart rhythm?

Arrhythmias (changes to heart rhythm) are documented as adverse reactions in the official safety profile. These include conditions such as atrial fibrillation and various types of tachycardia (fast heart rate). Serious, but uncommon, rhythm issues like ventricular fibrillation have also been reported.

Q: Is it true that Levosimendan can sometimes improve breathing difficulties?

Clinical studies examining the drug's effects report patterns related to the relief of heart failure-related symptoms. This includes improvements observed in the symptom of severe shortness of breath, also known as dyspnoea.

Q: Can other heart medications change how Levosimendan works?

According to official labeling, there is an increased risk of hypotension (low blood pressure) when Levosimendan is used alongside certain other intravenous vasoactive medicines or isosorbide mononitrate. However, the regulatory information also notes that the drug can be administered with beta-blocking agents without losing its therapeutic effect.

Q: Does Levosimendan replace a permanent heart failure treatment?

No, the drug is officially indicated for the short-term treatment of acutely decompensated severe chronic heart failure. It is intended to provide temporary hemodynamic support to stabilize patients in acute crisis, not to serve as a long-term replacement for permanent heart failure medications.

Q: Is Levosimendan used for all types of heart problems?

No, official product information limits its use to the short-term treatment of acutely decompensated severe chronic heart failure in specific situations where conventional therapy is not sufficient. It is not generally indicated for all types of heart conditions.

Q: Is it normal to feel temporary dizziness after treatment with Levosimendan?

Official safety profiles list dizziness as a common adverse effect. Other very common effects include hypotension (low blood pressure) and headache, which can be related to feelings of lightheadedness or dizziness.

Q: Are there any long-term effects of having received Levosimendan?

The majority of evidence comes from short-term clinical trials. While the effect of the active metabolite can last up to nine days, regulatory documents note that limited information is available for long-term clinical outcomes following the initial acute treatment period.

Q: Is Levosimendan safe for people with kidney problems?

The drug is generally excluded from use in patients with severe kidney impairment. The labeling notes the requirement to use the drug with caution in patients with mild to moderate kidney impairment, which requires an extended period of patient monitoring.

Q: Is Levosimendan available in a pill form?

No, the approved pharmaceutical form is a concentrate for solution for infusion. It is designed to be administered only via a controlled intravenous infusion in a hospital setting.

Q: How quickly should I expect to see the effects of Levosimendan during administration?

A patient's response to the treatment is generally assessed by medical staff within 30 to 60 minutes of a dose change. Clinical studies have shown that the maximum beneficial effects on key heart function parameters typically occur between 6 hours and 24 hours after the start of the infusion.

Q: Is Levosimendan widely used outside of Europe?

The drug has received marketing authorization in approximately 60 countries worldwide. A drug's availability in any region is dependent on the specific regulatory approval status granted by the local health regulatory agencies.

Q: What is the general safety classification of Levosimendan?

Official regulatory information classifies Levosimendan as a prescription-only medicine. Its administration is restricted to a hospital setting where facilities are available for continuous, adequate patient monitoring.

Q: What is the difference between Levosimendan and Dobutamine?

Levosimendan's pharmacological mechanism is described as that of a calcium sensitizer. This action is described as modulating heart muscle contraction without the significant increase in myocardial oxygen consumption often associated with older inotropic agents like Dobutamine.

Q: What is the maximum number of times a person can receive Levosimendan treatment?

The recommended treatment duration for the acute heart failure indication is a single 24-hour continuous intravenous infusion. The product labeling focuses on this single, short-term protocol.

Q: Do doctors use Levosimendan in surgery settings?

Research has specifically examined the use of Levosimendan to support heart function in patients who are at risk of or who have developed low cardiac output syndrome (LCOS) following major heart surgery.

Q: Why is the infusion time for Levosimendan so long?

The 24-hour infusion is linked to the drug's metabolism and its prolonged effects. This duration helps ensure the proper formation of a pharmacologically active metabolite (OR-1896), which contributes to the observed lasting hemodynamic effect for several days after the infusion is complete.

Q: Can Levosimendan be used for high blood pressure?

The drug is officially indicated for acute severe heart failure. Due to its action as a vasodilator, hypotension (low blood pressure) is listed as a very common side effect. It is not indicated for the treatment of high blood pressure.

Q: Is there a generic version of Levosimendan?

Yes, Levosimendan is available under various generic names in countries where it has received marketing authorization.

Q: Why is Levosimendan not available everywhere?

A drug's availability globally is dependent on the marketing authorization and approval status granted by the health regulatory agencies in each individual country.

Q: Does Levosimendan have any known long-term drug interactions?

Given that the drug is used for acute, short-term treatment, the active metabolite's effects and the requirement for monitoring can persist for approximately 7 to 10 days after the infusion is complete. The full profile for interactions beyond this period is not detailed in the acute-use labeling.

How to Store and Dispose of Levosimendan

Storage and disposal requirements for Levosimendan concentrate for solution for infusion are strictly defined in official regulatory labeling to ensure product integrity.

Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator (2 C to 8 C); Do not freeze
Protection	Keep the vial in the original outer carton to protect from light
Stability	Unopened shelf-life is typically 3 years. The diluted solution is chemically stable for 24 hours but is microbiologically recommended for immediate use

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. This instruction applies to pharmaceutical waste generated during its use.